Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zevra Therapeutics, Inc. (ZVRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, Zevra uses current reports on Form 8-K and other periodic filings to communicate material events, financial results, and governance changes related to its rare disease business.
Investors can review Form 8-K filings in which Zevra reports quarterly financial results and corporate updates, including revenue from its commercial products for Niemann-Pick disease type C and certain urea cycle disorders, operating expenses, and information about conference calls and webcasts. Other 8-K filings detail matters such as the resignation and transition of key officers, appointment of interim financial leadership, and board-level changes, along with summaries of related agreements and compensation terms.
These filings also document equity inducement awards granted under Zevra’s employment inducement award plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing transparency into stock option grants to new employees. Together with annual and quarterly reports (when available), the filings offer a structured view of Zevra’s financial condition, capital structure, and risk disclosures as it advances therapies like MIPLYFFA and OLPRUVA and develops candidates such as celiprolol.
On Stock Titan, SEC documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR help users see new Zevra filings as they appear, while specialized views of Forms 3, 4, and 5 make it easier to track insider transactions. For long-form reports such as 10-K and 10-Q, AI-generated highlights can help users quickly identify important sections on revenue drivers, research and development spending, and material risks related to Zevra’s rare disease portfolio.
Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage rare disease company focused on expanding access to treatments for underserved patient populations. The company’s lead product, MIPLYFFA (arimoclomol), became the first FDA‑approved therapy for Niemann‑Pick disease type C in September 2024 and is marketed in combination with miglustat in the United States. Zevra also runs a global expanded access program and has filed a Marketing Authorization Application in the European Union, now under EMA review.
Following approval, Zevra received and then sold a rare pediatric disease priority review voucher, generating $148.3 million of net proceeds that strengthen its balance sheet. The acquisition of Acer Therapeutics in 2023 added OLPRUVA for urea cycle disorders and the late‑stage celiprolol program for Vascular Ehlers‑Danlos syndrome, where a Phase 3 event‑driven trial (DiSCOVER) had 52 enrolled participants as of December 31, 2025. Zevra also earns royalties and potential milestones from the ADHD drug AZSTARYS and is advancing KP1077 for idiopathic hypersomnia and narcolepsy, supported by orphan designation and a Phase 2 trial that informed Phase 3 dosing plans.
Zevra Therapeutics reported a strong turnaround for 2025, with net revenue of $106.5 million, up from $23.6 million in 2024, driven mainly by $87.4 million in MIPLYFFA net revenue and higher expanded‑access and royalty income.
The company generated 2025 net income of $83.2 million, or $1.40 basic EPS, compared with a prior-year net loss of $105.5 million, helped by a $148.3 million gain on sale of a priority review voucher and despite a $58.7 million intangible asset impairment.
Q4 2025 net revenue reached $34.1 million and net income was $12.2 million. Cash, cash equivalents and securities totaled $238.9 million as of December 31, 2025, supporting continued investment in MIPLYFFA, OLPRUVA and the celiprolol VEDS program.
The company highlighted progress for MIPLYFFA in Niemann‑Pick type C, including growing U.S. uptake and an EMA marketing application under review, and ongoing enrollment in the Phase 3 DiSCOVER trial for celiprolol. Zevra also relocated its headquarters to Boston and appointed Justin Renz as Chief Financial Officer, with a $520,000 base salary and options to purchase 300,000 shares vesting over four years.
Zevra Therapeutics President and CEO Neil F. McFarlane reported equity award vesting and a planned share sale. On February 7, 2026, 37,500 restricted stock units vested, converting into the same number of common shares as part of an award that vests in three annual installments.
On February 9, 2026, McFarlane sold 14,625 shares of common stock at a weighted average price of $8.5597 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 21, 2025. Following these transactions, he directly holds 387,225 common shares and 75,000 restricted stock units.
Zevra Therapeutics SVP, Finance & Corp Controller Timothy J. Sangiovanni reported a planned stock sale. On 02/03/2026, he sold 3,000 shares of Zevra Therapeutics common stock in open-market transactions at a weighted average price of $9.1827 per share.
The trades were executed in multiple lots at prices ranging from $8.93 to $9.52, and were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03/28/2025. After this sale, he directly beneficially owns 29,590 Zevra common shares.
Zevra Therapeutics’ Chief Commercial Officer Joshua Schafer reported a pre-planned stock sale. On 02/03/2026, he sold 10,500 shares of Zevra Therapeutics common stock at a weighted average price of $9.1905 per share under a Rule 10b5-1(c) trading plan adopted on 03/27/2025. After this sale, he beneficially owned 62,278 shares held directly.
Zevra Therapeutics SVP Timothy J. Sangiovanni reported stock transactions involving common shares and restricted stock units. On January 30, 2026, he settled 6,333 restricted stock units into common stock and sold 1,750 shares at a weighted average price of $8.824 under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 28, 2025.
On January 31, 2026, he settled another 11,666 restricted stock units into common stock. Following these transactions, he directly beneficially owned 32,590 shares of common stock and held remaining restricted stock units that continue to vest over time, subject to his continued service.
Zevra Therapeutics insider Rahsaan W. Thompson, the Chief Legal & Compliance Officer and Secretary, reported multiple equity transactions in late January 2026. On January 29, he received 37,500 restricted stock units, which start vesting on January 29, 2027 in yearly installments, and a stock option for 75,000 shares at $8.86 per share that vests over four years and expires in 2036.
On January 30, one third of a prior restricted stock unit grant, or 11,333 units, vested and converted into common shares. The same day, he sold 4,080 common shares at a weighted average price of $8.8259 under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, leaving him with 49,919 common shares held directly.
Zevra Therapeutics’ Chief Medical Officer, Adrian W. Quartel, reported several equity transactions. On January 29, 2026, he received 37,500 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 75,000 shares at an exercise price of $8.86.
The new RSUs will vest one third on January 29, 2027, with the remaining two thirds vesting in equal annual installments, subject to continued service. The stock option vests in four equal annual installments beginning on the first anniversary of the grant date, also subject to continued service.
On January 30, 2026, 11,333 RSUs vested and settled into common shares, and Quartel sold 4,533 shares at a weighted average price of $8.8321 under a Rule 10b5‑1(c) trading plan adopted on March 26, 2025, leaving 9,723 common shares held directly and 22,667 RSUs outstanding.
Zevra Therapeutics chief commercial officer Joshua Schafer reported multiple equity compensation events and a small share sale. On January 29, he received 37,500 restricted stock units and a stock option for 75,000 shares at $8.86 per share. On January 30, 11,333 RSUs vested and converted into common stock, and he sold 3,375 shares at a weighted average price of $8.8297 under a pre‑adopted Rule 10b5‑1(c) trading plan dated March 27, 2025. On January 31, a further 35,334 RSUs vested into common stock. The new RSU and option awards vest in multi‑year installments, contingent on his continued service.
Zevra Therapeutics President and CEO Neil F. McFarlane, who also serves as a director, reported several equity transactions. On February 2, 2026, he sold 91,000 shares of common stock at a weighted average price of
On January 31, 2026, 233,334 restricted stock units (RSUs) vested and settled into the same number of common shares, increasing his directly held common stock to 455,350 shares before the subsequent sale and reducing his RSU balance to 233,333 units. Earlier, on January 29, 2026, he received equity awards of 125,000 RSUs and a 250,000-share stock option with a